Evidence map›Paper›PMID 41395285›Full record

ArticleAmerican journal of cancer research2025

USP18 promote tumor immune evasion in pancreatic cancer through enhancing autolysosome-mediated degradation of MHC-I.

Yan Fang, Jiaqiang Wang, Baoliang Fu, Yuanchun Yu, Qinrong Mao, Meizhen Yao, Xin Yu, Jing Cai

Abstract read
In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yan FangDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang University Nanchang, Jiangxi, China.
Jiaqiang WangDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang University Nanchang, Jiangxi, China.
Baoliang FuDepartment of General Surgery, Yushan County Hospital of Traditional Chinese Medicine Affiliated to Jiangxi University of Traditional Chinese Medicine Shangrao, Jiangxi, China.
Yuanchun YuDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang University Nanchang, Jiangxi, China.
Qinrong MaoDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang University Nanchang, Jiangxi, China.
Meizhen YaoDepartment of Gynaecology and Obstetrics, The Second Affiliated Hospital of Nanchang University, Nanchang University Nanchang, Jiangxi, China.
Xin YuHepatopancreatobiliary Surgery Division, Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang University Nanchang, Jiangxi, China.
Jing CaiDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang University Nanchang, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer, a lethal malignancy with a 5-year survival rate below 9%, is characterized by an immunosuppressive tumor microenvironment that facilitates immune evasion. Despite the clinical urgency, the molecular mechanisms driving the scarcity of cytotoxic T lymphocyte (CTL) infiltration, a hallmark of its immunologically 'cold' phenotype, remain poorly defined, which represents a critical barrier to developing effective immunotherapies. In this study, we identify ubiquitin-specific peptidase 18 (USP18) as a critical regulator of major histocompatibility complex I (MHC-I) degradation that enables immune evasion in pancreatic ductal adenocarcinoma (PDAC). In clinical PDAC samples, USP18 protein levels were significantly elevated and inversely correlated with MHC-I expression, independent of transcriptional regulation. Functionally, USP18 knockdown enhanced MHC-I surface expression, promoted CD8

Indexed as

immune evasionMHC-INBR1Pancreatic cancerUSP18

Identifiers

PMID41395285
PMCPMC12696528

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.